TP53 and breast carcinoma: Overall, the treatment of breast cancers with doxorubicin and epirubicin results in permanent DNA damage which in turn activates p53-mediated and p53-independent apoptosis pathways, resulting in cytotoxicity (Pommier et al. 2016).